Moderna Shares Fall 17.57%, Leaving Year-to-Date Gain at 587%

Moderna (MRNA) shares fell 17.6% on Oct. 22 after Phase 3 trial results for its cancer vaccine were leaked. The drop occurred despite positive results for the vaccine, developed with Merck (MRK). Analysts attributed the decline to a 'sell the news' event, with Bernstein maintaining a $45 price target and Wells Fargo suggesting concerns may be overdone. Merck shares also dropped 1.76%.

Moderna shares dropped 25% after leaked cancer vaccine data, despite positive results. The vaccine, developed with Merck, reduced recurrence or death risk by 42% in melanoma patients. Analysts noted the data was positive but investors had high expectations. Merck shares fell 1%.

Moderna and Merck released early phase 3 trial data for their mRNA-based skin cancer vaccine, showing a 42% reduction in recurrence or death risk compared to a single treatment. The trial involved 1,137 high-risk melanoma patients. Both companies plan to seek regulatory approval. Moderna's stock dropped following the announcement.

Moderna and Merck shares fell after leaked data on their personalized melanoma vaccine underwhelmed investors. The companies had previously reported promising results in August, leading to a surge in their stock prices. According to the report, the new data did not confirm the initial optimism.

Moderna and Merck reported that their mRNA cancer vaccine, intismeran, reduced death or recurrence risk by 42% in a late-stage melanoma trial. The vaccine, combined with Merck's Keytruda, showed improved recurrence-free and metastasis-free survival rates compared to Keytruda alone. The companies plan to seek regulatory approval and presented the data at a medical conference.

Moderna and Merck's mRNA cancer vaccine, intismeran, reduced melanoma recurrence risk by 42% in a study. The vaccine, tailored to each patient's tumor, was tested on 1,100+ high-risk melanoma patients. Moderna shares dropped 18% after results were released, despite being 200% higher since August.